We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tenet Healthcare has $2.1 billion left under its buyback authorization while funding growth.
Tenet Healthcare Corporation (THC - Free Report) is becoming more aggressive with shareholder returns, and its improving cash generation is making that strategy easier to support. In the first half of 2026, net cash provided by operating activities rose 27.1% year over year to $2.2 billion, while adjusted free cash flow totaled $1.4 billion. That momentum also prompted Tenet Healthcare to raise its 2026 adjusted free cash flow guidance (after noncontrolling interests) to $1.825-$2.055 billion, strengthening the financial backdrop for continued buybacks.
The company has already stepped up repurchases meaningfully. THC spent around $1.4 billion on share buybacks during the first half of 2026, including $1 billion in the second quarter. Its board also increased the repurchase authorization by $2 billion, leaving about $2.1 billion available as of July 23, 2026. This gives THC substantial room to keep returning cash if operating trends remain favorable.
However, buybacks are only one part of the capital-allocation picture. Tenet Healthcare is also investing in USPI expansion, higher-acuity services and other growth initiatives while maintaining sizable capital expenditure requirements. The company expects capital spending of $700-$800 million in 2026, underscoring the need to preserve cash for organic growth alongside shareholder returns. Debt service remains another consideration even after Tenet extended maturities through its recent refinancing.
Thus, the sustainability of Tenet Healthcare’s capital-return strategy hinges on maintaining strong cash conversion while funding growth and managing leverage. If operating momentum holds, THC should have room to remain active on buybacks without significantly limiting investment in its ambulatory platform.
How Are Peers Faring?
Some of THC’s peers in the medical space are Universal Health Services, Inc. (UHS - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) .
Universal Health Services is also balancing buybacks with sizable reinvestment needs. UHS repurchased $447.5 million of shares in the first half of 2026 and had approximately $977.6 million of remaining share repurchase authorization as of June 30, 2026, although planned capital spending of $950 million-$1.1 billion keeps reinvestment demands elevated.
HCA Healthcare is also maintaining a strong capital-return pace alongside heavy investment. It repurchased shares worth $3.6 billion in the first half of 2026 and paid dividends worth $354 million. As of June 30, 2026, HCA had $7.2 billion remaining under its buyback authorization while keeping its 2026 capital spending outlook at $5-$5.5 billion.
THC’s Price Performance, Valuation & Estimates
Shares of Tenet Healthcare have gained 27.9% over the past year compared with the industry’s growth of 8.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, Tenet Healthcare trades at a forward price-to-earnings ratio of 12.34, above the industry average of 10.89. THC carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $21.04 per share, implying 25.4% growth from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?
Key Takeaways
Tenet Healthcare Corporation (THC - Free Report) is becoming more aggressive with shareholder returns, and its improving cash generation is making that strategy easier to support. In the first half of 2026, net cash provided by operating activities rose 27.1% year over year to $2.2 billion, while adjusted free cash flow totaled $1.4 billion. That momentum also prompted Tenet Healthcare to raise its 2026 adjusted free cash flow guidance (after noncontrolling interests) to $1.825-$2.055 billion, strengthening the financial backdrop for continued buybacks.
The company has already stepped up repurchases meaningfully. THC spent around $1.4 billion on share buybacks during the first half of 2026, including $1 billion in the second quarter. Its board also increased the repurchase authorization by $2 billion, leaving about $2.1 billion available as of July 23, 2026. This gives THC substantial room to keep returning cash if operating trends remain favorable.
However, buybacks are only one part of the capital-allocation picture. Tenet Healthcare is also investing in USPI expansion, higher-acuity services and other growth initiatives while maintaining sizable capital expenditure requirements. The company expects capital spending of $700-$800 million in 2026, underscoring the need to preserve cash for organic growth alongside shareholder returns. Debt service remains another consideration even after Tenet extended maturities through its recent refinancing.
Thus, the sustainability of Tenet Healthcare’s capital-return strategy hinges on maintaining strong cash conversion while funding growth and managing leverage. If operating momentum holds, THC should have room to remain active on buybacks without significantly limiting investment in its ambulatory platform.
How Are Peers Faring?
Some of THC’s peers in the medical space are Universal Health Services, Inc. (UHS - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) .
Universal Health Services is also balancing buybacks with sizable reinvestment needs. UHS repurchased $447.5 million of shares in the first half of 2026 and had approximately $977.6 million of remaining share repurchase authorization as of June 30, 2026, although planned capital spending of $950 million-$1.1 billion keeps reinvestment demands elevated.
HCA Healthcare is also maintaining a strong capital-return pace alongside heavy investment. It repurchased shares worth $3.6 billion in the first half of 2026 and paid dividends worth $354 million. As of June 30, 2026, HCA had $7.2 billion remaining under its buyback authorization while keeping its 2026 capital spending outlook at $5-$5.5 billion.
THC’s Price Performance, Valuation & Estimates
Shares of Tenet Healthcare have gained 27.9% over the past year compared with the industry’s growth of 8.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, Tenet Healthcare trades at a forward price-to-earnings ratio of 12.34, above the industry average of 10.89. THC carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $21.04 per share, implying 25.4% growth from the year-ago period.
Image Source: Zacks Investment Research
THC stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.